Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.
3.
4.

Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease.

Hattori N, Hasegawa K, Sakamoto T.

J Clin Pharm Ther. 2012 Oct;37(5):571-7. doi: 10.1111/j.1365-2710.2012.01336.x. Epub 2012 Mar 6.

PMID:
22390368
5.
6.

High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.

Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C.

Clin Neuropharmacol. 2003 May-Jun;26(3):146-50.

PMID:
12782917
7.

Ropinirole for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2001;(1):CD001516. Review.

PMID:
11279718
8.
9.

Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.

Lew MF, Somogyi M, McCague K, Welsh M; Lce QoL Study Group.

Int J Neurosci. 2011 Nov;121(11):605-13. doi: 10.3109/00207454.2011.598982. Epub 2011 Aug 16.

PMID:
21843110
10.

Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.

Delea TE, Thomas SK, Hagiwara M, Mancione L.

Curr Med Res Opin. 2010 Jul;26(7):1543-52. doi: 10.1185/03007991003780628.

PMID:
20429819
11.

Ropinirole for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2000;(3):CD001516. Review. Update in: Cochrane Database Syst Rev. 2001;(1):CD001516.

PMID:
10908503
12.

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group.

Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878.

PMID:
18846551
13.

Ropinirole therapy for Parkinson's disease.

Pahwa R, Lyons KE, Hauser RA.

Expert Rev Neurother. 2004 Jul;4(4):581-8. Review.

PMID:
15853577
14.
15.

A review of ropinirole prolonged release in Parkinson's disease.

Nashatizadeh MM, Lyons KE, Pahwa R.

Clin Interv Aging. 2009;4:179-86. Epub 2009 May 14. Review.

16.

[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].

Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, Pavon N, Macias R, Luquin MR, Hernandez B, Grandas F, Gimenez-Roldan S, Tolosa E, Obeso JA.

Neurologia. 2005 May;20(4):180-8. Review. Spanish.

PMID:
15891947
17.

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.

Ann Neurol. 2010 Jul;68(1):18-27. doi: 10.1002/ana.22060. Erratum in: Ann Neurol. 2010 Sep;68(3):412-3.

PMID:
20582993
18.

Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2001;(1):CD001517. Review.

PMID:
11279719
19.

Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke CE, Deane KH.

Cochrane Database Syst Rev. 2000;(3):CD001517. Review. Update in: Cochrane Database Syst Rev. 2001;(1):CD001517.

PMID:
10908504
20.

Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.

Pahwa R.

J Am Med Dir Assoc. 2006 Sep;7(7 Suppl 2):4-10. Review.

PMID:
17948613

Supplemental Content

Support Center